HONG KONG – With an eye on an innovative biologic therapy that fulfills an unmet need in Asia, Shanghai-based biotech Imab purchased the exclusive Asian rights for a potential biologic drug for autoimmune diseases from Swiss company Ferring Pharmaceuticals SA. Read More
HONG KONG – Pfizer Inc. (NYSE:PFE) will partner with Suzhou-based Pegbio Co. Ltd. to develop glucokinase activator (GKA) drugs for China as part of the multinational's strategy of using local partners to further the development of innovative drugs that address unmet needs in China. Read More
HONG KONG — A neurotrophic brain protein has been shown to play an important role in how well cancer patients respond to chemotherapy, according to the findings of a new Chinese study reported Dec. 17, 2016, during the European Society for Medical Oncology (ESMO) Asia 2016 Congress in Singapore. Read More
SHANGHAI – Small-molecule oncology drug developer, Ascentage Pharma Group, of Taizhou, Zhejiang, has raised ¥500 million (US$72 million) from Future Industry Investment Fund, a private equity fund managed by China's State Development & Investment Corporation Fund Management Corp. Ltd. (SDIC). Read More
DUBLIN – Chicago Cubs fans excepted, 2016 was a bad year for many for a whole host of reasons. The travails of the Australian cell therapy developer Mesoblast Ltd. may not have registered broadly, but the firm had a torrid year. Read More
SHANGHAI – The latest Chinese biopharma to receive a generous round of financing, Ascletis Pharmaceuticals Co. Ltd., of Hangzhou and Shaoxing, received $100 million from China-based venture capital firms. Read More
